Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price increased by research analysts at BMO Capital Markets from $177.00 to $180.00 in a research note issued on Friday. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 65.75% from the stock’s previous close.
ALXN has been the topic of a number of other reports. TheStreet lowered Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. BidaskClub raised Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price on the stock in a research report on Tuesday, October 31st. Credit Suisse Group reaffirmed a “buy” rating and issued a $166.00 target price on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $130.00 target price (down from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty-one have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $153.14.
Alexion Pharmaceuticals (ALXN) opened at $108.60 on Friday. The firm has a market capitalization of $24,260.00, a P/E ratio of 55.13, a price-to-earnings-growth ratio of 0.91 and a beta of 1.16. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.51.
In related news, CFO Paul J. Clancy sold 6,079 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $707,048.49. Following the sale, the chief financial officer now directly owns 95,093 shares of the company’s stock, valued at approximately $11,060,266.83. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Heidi L. Wagner sold 655 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $117.26, for a total value of $76,805.30. Following the sale, the senior vice president now directly owns 32,635 shares in the company, valued at $3,826,780.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,930 shares of company stock worth $3,378,199. Corporate insiders own 4.35% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC raised its position in shares of Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after acquiring an additional 4,682,336 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Alexion Pharmaceuticals by 4,509.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after acquiring an additional 864,967 shares in the last quarter. Factory Mutual Insurance Co. raised its position in shares of Alexion Pharmaceuticals by 104.5% during the 4th quarter. Factory Mutual Insurance Co. now owns 358,500 shares of the biopharmaceutical company’s stock valued at $42,873,000 after acquiring an additional 183,200 shares in the last quarter. Creative Planning increased its position in Alexion Pharmaceuticals by 72.2% in the fourth quarter. Creative Planning now owns 27,773 shares of the biopharmaceutical company’s stock worth $3,321,000 after buying an additional 11,642 shares during the period. Finally, USA Financial Portformulas Corp acquired a new stake in Alexion Pharmaceuticals in the third quarter worth $3,632,000. 94.04% of the stock is currently owned by institutional investors and hedge funds.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.